Age, Biography and Wiki

Rudi Pauwels was born on 1960, is a Belgian pharmacologist and entrepreneur. Discover Rudi Pauwels's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 64 years old?

Popular As N/A
Occupation Pharmaceutical scientist and biotech entrepreneur
Age 64 years old
Zodiac Sign N/A
Born
Birthday
Birthplace N/A
Nationality

We recommend you to check the complete list of Famous People born on . He is a member of famous entrepreneur with the age 64 years old group.

Rudi Pauwels Height, Weight & Measurements

At 64 years old, Rudi Pauwels height not available right now. We will update Rudi Pauwels's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.

Physical Status
Height Not Available
Weight Not Available
Body Measurements Not Available
Eye Color Not Available
Hair Color Not Available

Dating & Relationship status

He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.

Family
Parents Not Available
Wife Not Available
Sibling Not Available
Children Eline Powell

Rudi Pauwels Net Worth

His net worth has been growing significantly in 2023-2024. So, how much is Rudi Pauwels worth at the age of 64 years old? Rudi Pauwels’s income source is mostly from being a successful entrepreneur. He is from . We have estimated Rudi Pauwels's net worth, money, salary, income, and assets.

Net Worth in 2024 $1 Million - $5 Million
Salary in 2024 Under Review
Net Worth in 2023 Pending
Salary in 2023 Under Review
House Not Available
Cars Not Available
Source of Income entrepreneur

Rudi Pauwels Social Network

Instagram
Linkedin
Twitter
Facebook
Wikipedia Rudi Pauwels Wikipedia
Imdb

Timeline

1960

Rudi Pauwels (born 1960) is a Belgian pharmacologist and biotech entrepreneur.

He was one of the first researchers in the field of HIV, and he played a key role in the fight against the AIDS pandemic by discovering several widely used anti-HIV drugs during his doctorate studies at the Rega Institute (Leuven, Belgium) and while leading biotech companies Tibotec and Virco.

1983

He studied pharmaceutical sciences at the Katholieke Universiteit Leuven (KU Leuven), Belgium, and graduated as a pharmacist in 1983.

Within a year after the 1983 discovery of HIV, the viral pathogen that causes AIDS, Pauwels began work on the topic while still a doctorate student.

1984

In 1984, in the laboratory of Professor Erik De Clercq at the Rega Institute (University of Leuven, Belgium), he started to develop the first laboratory models in search of new anti-HIV compounds.

The methods he published were widely used by fellow scientists that joined the search for new anti-AIDS (HIV) treatments.

1987

In 1987, Pauwels obtained a research fellowship of the Janssen Research Foundation, which started a long-standing collaboration and close friendship with the late Dr. Paul Janssen, founder of Janssen Pharmaceuticals.

Janssen became a mentor and would influence his pharmaceutical work.

1990

In 1990, the Janssen-funded collaboration of his small team at the Rega Institute would lead to the discovery of the first non-nucleoside reverse transcriptase inhibitor (NNRTI).

It was also Janssen who would introduce him to Dr. Paul Stoffels, with whom he would collaborate at Tibotec, Virco and Johnson & Johnson.

Pauwels obtained his Ph.D. in pharmaceutical sciences from the KU Leuven in 1990 with greatest distinction (maxima cum laude), with De Clercq and Janssen as his promotors.

His thesis was entitled "Development of new agents against the Human Immunodeficiency Virus (HIV)".

A few years after obtaining his Ph.D. and leading a small group of researchers at the Rega Institute, Pauwels began to work on the problem of HIV drug resistance.

1994

Since 1994 he has either founded or co-founded several biotech companies, specialising in personalized and high precision medicine.

His current roles include founder and president of the Praesens Foundation, chairman of Praesens Care, executive chairman of IMEC/Johns Hopkins spin-off company miDiagnostics and board positions in various companies and research institutes.

He is an author of more than 150 peer-reviewed papers and recipient of numerous awards and distinctions.

In 1994, he founded the anti-HIV drug discovery company Tibotec together with his wife, pharmacist Carine Claeys.

A year later they founded, together with Paul Stoffels, the diagnostics company Virco, which would develop HIV-treatment diagnostic services that would help physicians select the optimal therapy for their patients (e.g. Antivirogram).

1999

In 1999, Pauwels was one of the driving forces behind the creation of the Tibotec spin-out, Galapagos Genomics, that would combine functional genomic technologies from Tibotec and Crucell, a Dutch-based biotech company.

2000

In early 2000, it became clear to Pauwels that the future of medicine was increasingly depending on our molecular insights of disease.

New generations of drugs would target the underlying molecular dysfunctional processes.

It meant that measuring relevant biomarkers would become even more essential.

But experiences from the global AIDS crisis and Virco in particular, taught him that the operational model of sending samples from patients to central laboratories was time-consuming and wasteful.

It appeared that his approach did not scale easily around the world.

Ideally, the lab functionality needed to come (in miniaturized format) to patients and their direct environment, not the other way around.

During his Ph.D. studies, he broadened his interests beyond virology into software programming and robotics.

2002

Tibotec-Virco was acquired by Johnson & Johnson in 2002, after which Pauwels became vice president of Johnson & Johnson's global anti-infectives drug discovery group, focusing on Hepatitis C and respiratory diseases.

Here, he worked on drugs and diagnostics for respiratory diseases.

2003

In the middle of the SARS crisis in 2003, he started a project to develop an anti-SARS drug discovery system that, in 2020, was used as the basis for efforts to find inhibitors for SARS-CoV-2.

This effort, involving a number of pharmaceutical companies, occurred at the Rega Institute, continuing the work based on his original large-scale anti-HIV drug screening and recently received funding from the Bill & Melinda Gates Foundation.

The work of Pauwels and his colleagues resulted in several drugs that were successfully introduced for modern antiviral AIDS therapies.

They include next-generation anti-HIV compounds by Tibotec/Johnson & Johnson, Prezista, Intelence and Edurant, as well as the direct precursor to Gilead Sciences' Viread.

These drugs, together with the diagnostic technologies by Virco, have helped to turn AIDS into the chronic, manageable disease it is today, for those who have access to the medicines.

The drugs have also generated several billion dollar revenues yearly, providing returns for investors and shareholders and helping to finance the R&D for the treatment of important diseases.

2004

Realizing the need for better, scalable diagnostics at the point of need, he decided in 2004 to go on a three-year sabbatical at the Swiss Federal Institute of Technology-EPFL in Lausanne (Switzerland), one of the leading research centres in micro- and nano-technology.

2007

In 2007, he created Biocartis, a molecular diagnostics company that would develop and commercialize the Idylla platform, a fully integrated and automated sample-to-molecular diagnostic (PCR) result solution.

The company grew rapidly and was taken public.

The company offered precision diagnostics for cancer therapies, but there was ultimately no broader support for his expansion plans into infectious diseases.

2017

After leading the company for a decade, he decided in 2017 to further pursue his interests in infectious diseases.

2020

In 2020 he was appointed as co-chair of the Diagnostics R&D Working Group of the Access to COVID-19 Tools Accelerator.